Revelation Biosciences, Inc.

NasdaqCM:REVB Stock Report

Market Cap: US$4.1m

Revelation Biosciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

James Rolke

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage38.64%
CEO tenure6yrs
CEO ownership2.5%
Management average tenure6yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 06

Revelation Biosciences surges 46% on licensing deal with Vanderbilt University

Revelation Biosciences (NASDAQ:REVB) is trading 45.7% higher premarket after it announced an exclusive license agreement with Vanderbilt University, Nashville to develop and commercialize its drug, phosphorylated hexaacyl disaccharide (PHAD), for treating or preventing infections. The license covers potential applications such as prevention or reduction of acquired infections including those resulting from surgery, severe burns, and antibiotic resistance. Preclinical studies have shown treatment with PHAD significantly reduces the duration and severity of infection by augmenting the innate immune response, a form of trained immunity.
Seeking Alpha • Aug 15

Revelation Biosciences GAAP EPS of -$0.12

Revelation Biosciences press release (NASDAQ:REVB): Q2 GAAP EPS of -$0.12. As of June 30, 2022, Revelation had $3.5 million in cash and cash equivalents, compared to $1.3 million as of December 31, 2021.
Seeking Alpha • Jul 26

Revelation Biosciences stock slides 47% on pricing $5M securities offering

Revelation Biosciences (NASDAQ:REVB) shares dropped 47% pre-market on Tuesday after the life sciences company priced its $5M securities offering. The offering consists of 8.33M shares of common stock and warrants to purchase up to 8.33M common shares at a price of $0.60 per share and associated warrant. The warrants are exercisable upon issuance at $0.60/share and will expire five years following the date of issuance. Offering is expected to close around July 28, 2022. Gross proceeds are expected to be ~$5M; net proceeds will be used to further the development of REVTx-99b, REVTx-200 and REVTx-300; continue to develop other products and therapies; and fund working capital and general corporate purposes using any remaining amounts.
Seeking Alpha • Mar 28

Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections

Revelation Biosciences is developing therapeutic and diagnostic products for respiratory viral infections based on innate immune response. The Company has just completed a Phase 2 viral challenge study of the lead therapeutic candidate and data analysis is expected in 2Q-2022. The Company plans regulatory submission for its diagnostic candidate in 2H-2022.

CEO Compensation Analysis

How has James Rolke's remuneration changed compared to Revelation Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$22m

Dec 31 2025US$2mUS$589k

-US$15m

Sep 30 2025n/an/a

-US$14m

Jun 30 2025n/an/a

-US$12m

Mar 31 2025n/an/a

-US$14m

Dec 31 2024US$813kUS$561k

-US$15m

Sep 30 2024n/an/a

-US$16m

Jun 30 2024n/an/a

-US$16m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$649kUS$475k

-US$120k

Sep 30 2023n/an/a

US$875k

Jun 30 2023n/an/a

US$2m

Mar 31 2023n/an/a

US$2m

Dec 31 2022US$480kUS$400k

-US$11m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$618kUS$400k

-US$12m

Sep 30 2021n/an/a

-US$11m

Dec 31 2020US$273kUS$167k

-US$4m

Compensation vs Market: James's total compensation ($USD1.52M) is above average for companies of similar size in the US market ($USD629.02K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.

CEO

James Rolke (56 yo)

6yrs
Tenure
US$1,524,531
Compensation

Mr. James M. Rolke serves as Chief Executive Officer and Director at Revelation Biosciences, Inc. since May 2020 and serves as its Chairman since June 3, 2025. Mr. Rolke has experience in the biotechnology...

Leadership Team

NamePositionTenureCompensationOwnership
James Rolke
Chairman & CEO6yrsUS$1.52m2.46%
$ 100.8k
Chester Zygmont
CFO & Corporate Secretary6yrsUS$1.19m2.31%
$ 94.4k
Sandra Vedrick
Vice President of Human Resources & Investor Relations6.3yrsno datano data
Carol Odle
Senior Director of Clinical Projectsno datano datano data
6.0yrs
Average Tenure

Experienced Management: REVB's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Rolke
Chairman & CEO6yrsUS$1.52m2.46%
$ 100.8k
Lakhmir Chawla
Independent Director2.6yrsUS$81.64k0.045%
$ 1.8k
Jess Roper
Independent Director5.6yrsUS$81.64k0.063%
$ 2.6k
Jennifer Carver
Independent Director6yrsUS$81.64k0.061%
$ 2.5k
Julia Bohannon
Member of Scientific Advisory Board3.2yrsno datano data
Antonio Hernandez
Member of Scientific Advisory Board3.2yrsno datano data
4.4yrs
Average Tenure
58yo
Average Age

Experienced Board: REVB's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/29 05:32
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Revelation Biosciences, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffRoth Capital Partners
Bradley SorensenZacks Small-Cap Research